热门资讯> 正文
Vera Therapeutics announces $200M public offering
2025-12-09 05:31
- Vera Therapeutics (NVSDAQ:ERA) stated on Monday that it had commenced a public offering to issue and sell $200M of shares, and the underwriters will have a 30-day option to purchase up to an additional 15% of the shares of Class A common stock.
- J.P. Morgan, Goldman Sachs & Co. LLC, Evercore ISI, and Cantor are acting as joint book-running managers for the proposed offering.
- LifeSci Capital is acting as lead manager for the proposed offering.
- The offering is being made pursuant to an automatic shelf registration statement that was filed with the SEC on October 28, 2024, and became effective upon filing.
More on Vera Therapeutics
- Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Vera Therapeutics: Stock Rises As IgAN Approval Chances Increase - I'm On Sidelines
- Vera Therapeutics, Inc. (VERA) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy Transcript
- Goldman's 48 potential M&A candidates
- Seeking Alpha’s Quant Rating on Vera Therapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。